Protalix BioTherapeutics (PLX) - Cash per Share

protalix.com - graphic logo of issuer PLX

Protalix BioTherapeutics (PLX) revenues rely on a single drug for Fabry disease, creating a single-product risk. The cash per share metric provided by GURU.Markets shows a value of 0.59. The company utilizes its unique ProCellEx platform for low-cost protein synthesis in plants, while royalties from Elfabrio ensure a steady stream of high-margin free cash flow.

PLX (Protalix BioTherapeutics Inc.) Cash Funds per Share history from 07/04/2022 to 11/20/2026

Analytical breakdowns for Protalix BioTherapeutics (PLX)

- stock value and consensus price forecast:
- cash availability and cash flow indicators:
Summary company analysis:PLX, Protalix BioTherapeutics, Inc
Original product of Protalix BioTherapeutics, Inc

This metric reflects the share of net liquid assets per common share, allowing for an assessment of the security's intrinsic value and the issuer's financial strength. By analyzing the cash per share trend, an investor can compare the rate of capital burn with the development of the unique plant-based platform of Protalix BioTherapeutics (PLX) within high-yield rare disease therapy niches.